Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ligand Pharmaceuticals Inc Partner Glaxosmithkline Plc announces results of phase 3 PETIT2 study of Eltrombopag in Pediatric Patients with Chronic Immune Thrombocytopenia


Friday, 13 Jun 2014 07:30am EDT 

Ligand Pharmaceuticals Inc:GlaxoSmithKline (GSK) plc present results from Phase 3 PETIT2 study evaluating efficacy of eltrombopag vs. placebo in pediatric patients with chronic immune (idiopathic) thrombocytopenic purpura (cITP).Eltrombopag marketed as Promacta in U.S. and as Revolade in Europe and other countries across world.Says Eltrombopag met its primary endpoint, achieving statistically significant improvement in platelet counts with almost 40 percent of patients treated with eltrombopag attaining consistent platelet response for 6 of 8 weeks compared to placebo (39.7 percent vs. 3.4 percent, respectively, p<0.001).PETIT2 study results were highlighted today as part of a Press Briefing and Oral Presentation at the European Hematology Association Annual Congress in Milan, Italy.GSk moving forward with planned regulatory submissions for a pediatric indication in cITP later this year. 

Company Quote

47.32
-0.06 -0.13%
22 Sep 2014